Efficacy of olopatadine ophthalmic solution 0.2% in reducing signs and symptoms of allergic conjunctivitis

Authors: Abelson, Mark B.¹; Gomes, Paul J.²; Pasquine, Terri³; Edwards, Michael R.³; Gross, Robert D.⁴; Robertson, Stella M.³

Source: Allergy and Asthma Proceedings, Volume 28, Number 4, July-August 2007 , pp. 427-433(7)

Publisher: OceanSide Publications, Inc

Buy & download fulltext article:

Price: $39.50 plus tax (Refund Policy)

Abstract:

Olopatadine hydrochloride ophthalmic solution 0.2% (Pataday, Alcon) is a new formulation of olopatadine hydrochloride ophthalmic solution, the first topical ocular antiallergic agent indicated for once-daily dosing. The aim of this study was to evaluate the safety, efficacy, onset, and duration of action of olopatadine 0.2% in the treatment of allergic conjunctivitis. Using the conjunctival allergen challenge, this double-masked, randomized by eye, parallel-group study included four visits over a 5-week period. Subjects were screened for eligibility (visit 1) and their ocular allergic responses were confirmed at visit 2. The efficacy of olopatadine in reducing the signs and symptoms of allergic conjunctivitis was evaluated at onset of action (visit 4) and 16 hours (visit 3) after masked medication instillation. The primary efficacy parameter was ocular itching. Safety parameters were also evaluated. Ninety subjects were evaluated. Olopatadine 0.2% was significantly (p < 0.001) more effective than placebo in the treatment of ocular itching at all time points at both the onset of action and the 16-hour allergen challenges. Olopatadine 0.2% was significantly (p < 0.03) more effective than placebo in the reduction of conjunctival redness, chemosis, and eyelid swelling at all time points (with the exception of conjunctival redness, which was significantly reduced at five of six time points). There were no serious adverse events and no treatment-related adverse events. Once-daily dosing with olopatadine 0.2% reduced the signs and symptoms of allergic conjunctivitis with a rapid and prolonged duration of action. Safety analyses indicated that olopatadine 0.2% was safe and well tolerated in subjects with a history of allergic conjunctivitis.

Keywords: Allergic conjunctivitis; allergy; clinical trial; conjunctival redness; double blind; ocular; olopatadine ophthalmic solution; placebo controlled; rhinoconjunctivitis; topical

Document Type: Research article

DOI: http://dx.doi.org/10.2500/aap.2007.28.3014

Affiliations: 1: Schepens Eye Research Institute and Harvard Medical School, Boston, Massachusetts; Ophthalmic Research Associates, North Andover, Massachusetts 2: Ophthalmic Research Associates, North Andover, Massachusetts 3: Alcon Laboratories, Inc., Fort Worth, Texas 4: University of Texas Southwestern Medical Center, Dallas, Texas

Publication date: 2007-07-01

More about this publication?

Allergy and Asthma Proceedings is a peer reviewed publication dedicated to distributing timely scientific research regarding advancements in the knowledge and practice of allergy, asthma and immunology. Its primary readership consists of allergists and pulmonologists.

The goal of the Proceedings is to publish articles with a predominantly clinical focus which directly impact quality of care for patients with allergic disease and asthma.

Featured topics include asthma, rhinitis, sinusitis, food allergies, allergic skin diseases, diagnostic techniques, allergens, and treatment modalities. Published material includes peer-reviewed original research, clinical trials and review articles.

The journal is indexed in Thomson Reuters Web of Science and Science Citation Index Expanded, plus the National Library of Medicine's PubMed service.
Editorial Board
Information for Authors
Submit a Paper
Information for Advertisers
Reprint Requests
ingentaconnect is not responsible for the content or availability of external websites

Efficacy of olopatadine ophthalmic solution 0.2% in reducing signs and symptoms of allergic conjunctivitis

Buy & download fulltext article:

Tools

Key

Text size:

Useful pages